- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05534347
Angiogenic Biomarkers in Juvenile Idiopathic Arthritis (MAJIC)
Angiogenic Inflammatory Biomarkers in Juvenile Idiopathic Arthritis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Juvenile idiopathic arthritis (JIA) is a heterogeneous group of chronic inflammatory rheumatic diseases beginning before the age of 16. The most common pediatric rheumatologic disease. JIA is the most common pediatric rheumatologic disease. Apart from clinical features and the biological inflammatory syndrome, no predictive parameter for the severity of JIA, especially polyarticular JIA, has been identified. The team has been interested in the prognosis of RA for many years. Thus, the investigators have conducted various studies in search of biological parameters associated with the joint prognosis of RA patients, which allowed the investigator to discover the interest of angiogenic and inflammatory biomarkers such as semaphorins and CCN1 protein. This has been demonstrated in vitro but also in vivo from sera of RA patients. These markers are associated with activity and structural damage in RA.
The project aims to study the interest of these same angiogenic biomarkers in the serum of JIA patients in order to establish whether, as in RA, they are also associated with disease severity.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Marie BENHAMMANI-GODARD
- Phone Number: +33 1 58411190
- Email: marie.godard@aphp.fr
Study Contact Backup
- Name: Yannick ALLANORE, PD, PhD
- Phone Number: 0033158412563
- Email: yannick.allanore@aphp.fr
Study Locations
-
-
IDF
-
Paris, IDF, France, 75014
- Recruiting
- Rheumatology Department, Cochin Hospital
-
Contact:
- Yannick ALLANORE, MD, PhD
- Phone Number: 0033158412572
- Email: yannick.allanore@aphp.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Greater than or equal to 16 years-old
- Diagnosis of Juvenile Idiopathic Arthritis with specialized follow up in Rheumatology at Cochin Hospital
- No-opposition to the research
- Patient with health insurance
- Mastery of the French language
Exclusion Criteria:
- Patient under curatorship or guardianship
- Patient receiving french state medical aid
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Juvenile Idiopathic Arthritis
Patients seen in a specialized rheumatology consultation for the management of juvenile idiopathic arthritis in an adult service, after information and collection of their non-opposition.
|
Addtional tube of blood needed for follow up of patients
Joint puncture if needed according to routine care of the patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dosage of angiogenic markers
Time Frame: 5 years
|
Dosage of angiogenic markers by ELISA method in serum. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up. |
5 years
|
Dosage of angiogenic markers
Time Frame: 5 years
|
Dosage of angiogenic markers by ELISA method in synovial fluid if available. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up. |
5 years
|
Dosage of inflammatory markers by ELISA method
Time Frame: 5 years
|
Dosage of inflammatory markers by ELISA method in serum. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up. |
5 years
|
Dosage of inflammatory markers by ELISA method
Time Frame: 5 years
|
Dosage of inflammatory markers by ELISA method in synovial fluid if available. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up. |
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Questionnaires
Time Frame: 5 years
|
Severity of JIA
|
5 years
|
Collection of treatments received
Time Frame: 5 years
|
Severity of JIA
|
5 years
|
Structural damage determined by x-rays
Time Frame: 5 years
|
Structural damage determined by x-rays during follow up.
|
5 years
|
Angiogenic biomarkers
Time Frame: At inclusion
|
Determine if sera angiogenic biomarkers are associated with clinical subtypes of JIA.
|
At inclusion
|
Inflammatory biomarkers
Time Frame: At inclusion
|
Determine if sera inflammatory biomarkers are associated with clinical subtypes of JIA.
|
At inclusion
|
Collaborators and Investigators
Investigators
- Principal Investigator: Yannick ALLANORE, PD, PhD, Cochin Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- APHP220364
- 2022-A00468-35 (Other Identifier: France : ANSM)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Juvenile Idiopathic Arthritis (JIA)
-
University of British ColumbiaUniversity of Manitoba; The Hospital for Sick Children; McGill University Health... and other collaboratorsRecruiting
-
AbbVieRecruitingJuvenile Idiopathic Arthritis (JIA)United States, Germany, Hungary, Israel, Puerto Rico, Spain, Japan, Canada, Italy, Sweden
-
Horizon Pharma Ireland, Ltd., Dublin IrelandCompletedJuvenile Idiopathic Arthritis (JIA)United States
-
National Institute of Allergy and Infectious Diseases...Autoimmunity Centers of Excellence (ACE); Feinstein Institute for Medical Research...RecruitingJuvenile Idiopathic Arthritis (JIA)United States
-
UCB BIOSCIENCES GmbHPRA Health SciencesCompletedPolyarticular-course Juvenile Idiopathic Arthritis (JIA)United States, Argentina, Brazil, Canada, Chile, Mexico, Russian Federation
-
AbbVieCompletedJuvenile Idiopathic Arthritis | JIAUnited States, Australia, Austria, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, Norway, Portugal, Puerto Rico, Slovakia, Spain, Sweden
-
The Hospital for Sick ChildrenCompleted
-
Joeri van StraalenCompletedSelf-Evaluation | JIANetherlands
-
Medical University of GrazCompletedJIA Associated Uveitis
Clinical Trials on Blood sample
-
Medical University of WarsawCompletedArthroplasty | Platelet Aggregation | Methylmethacrylate EmbolismPoland
-
Memorial Sloan Kettering Cancer CenterActive, not recruiting
-
Meir Medical CenterCompleted
-
University Hospital, ToursNot yet recruitingRenal Transplant | ConversionFrance
-
Centre Hospitalier Universitaire de BesanconRecruitingInvasive Pulmonary AspergillosisFrance
-
Centre Hospitalier Universitaire DijonRecruitingAutoimmune Hemolytic AnemiaFrance
-
M.D. Anderson Cancer CenterTerminated
-
Duke UniversityUniversity of South Florida; Children's Hospital Los AngelesCompletedInfant Immunity Response and Immunoglobulin DiversityUnited States
-
University Hospital, ToulouseCompleted